Click on the link below to jump to the main contents on this page.
july 26, 2013
Meiji Initiates Phase 1 Clinical Trial of Arbekacin Inhalation Solution (ME1100) in the U.S. and Enters into a Licensing Agreement with PARI Pharma for a Customized eFlow
Technology Inhalation Device
Apr 24, 2013
Meiji has launched a website for “Contracted development of microbial fermentation”
Apr 18, 2013
Meiji Initiates Phase 1 Clinical Trial of ME1111 in U.S. for Topical Treatment of Onychomycosis
Message from the President
In compliance with the Pharmaceutical Affairs Act, Meiji Seika Pharma appoints a...
Feb 13, 2014
Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2014(PDF:1030KB)
Nov 19, 2013
【Presentation】Financial Results for the First Half of Fiscal Year Ending March 31, 2014(PDF:1247KB)
Nov 12, 2013
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2014(PDF:1097KB)
Terms and Conditions
Meiji Holdings Co.,Ltd.